FDA approves adjuvant indication for Sutent in renal cell carcinoma

December 07, 2017

Vol.40 No.10

DOWNLOAD PDF TABLE OF CONTENTS

FDA approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of renal cell carcinoma returning after nephrectomy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Ruling changes NY law, restores oncologists ability to provide supportive therapies in-office

New York Cancer & Blood Specialists successfully challenged the New York State Department of Health’s restrictive definition of “oncologic protocol.”

November 01, 2024

Vol.50 No.41

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

August 02, 2024

Vol.50 No.31

By Donald A. Berry